Last reviewed · How we verify
NCT02788292
Effect of N-Acetylcysteine on Autologous Fat Graft Survival
Phase 4 trial testing Acetylcysteine in Adipose Tissue Atrophy. Withdrawn.
16 November 2020
Quick facts
| Lead sponsor | Nova Scotia Health Authority |
|---|---|
| Phase | Phase 4 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 15 August 2016 |
| Primary completion | 16 November 2020 |
| Estimated completion | 16 November 2020 |
Drugs / interventions tested
- Acetylcysteine (Acetylcysteine) — full drug profile →
Conditions studied
- Adipose Tissue Atrophy — all drugs for Adipose Tissue Atrophy →
- Deformity of Reconstructed Breast — all drugs for Deformity of Reconstructed Breast →
- Graft Loss — all drugs for Graft Loss →
Sponsor
Nova Scotia Health Authority — full company profile →
Who can join
Adults 18 to 45, female only, with Adipose Tissue Atrophy or Deformity of Reconstructed Breast. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A single-centre triple-blind study looking at the addition of NAC to tumescent solution for liposuction and fat grafting in healthy patient volunteers already undergoing bilateral breast reduction. Three-dimensional reconstructions and volumetric analysis will be performed based on CT scans at 0, 1 and 3 months and then histological analysis will be performed after fat graft explantation at 3 months to determine fat graft vascularity and quality.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02788292
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Acetylcysteine
Trials testing the same drug.
- NCT07414212 — Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosi · Phase 1, PHASE2 · recruiting
- NCT05070650 — Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold · Phase 3 · withdrawn
- NCT04918719 — Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke · Phase 2 · completed
- NCT05258682 — Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease · Phase 1, PHASE2 · unknown
- NCT05804123 — LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media · NA · completed
Other Nova Scotia Health Authority trials
Trials by the same sponsor.
- NCT03716999 — Starlight Therapy in Palliative Care · not yet recruiting
- NCT06987409 — Continuous Erector Spinae Block for Analgesia Following Lumbar Decompression · NA · not yet recruiting
- NCT06575621 — Knee-hip Surgery Wait-list Support Program · NA · not yet recruiting
- NCT07143162 — YOGA-FIT: Protocol for a Crossover Trial Investigating the Feasibility and Impact of Yoga for People With Stroke · NA · not yet recruiting
- NCT07239999 — Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02788292 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nova Scotia Health Authority
- Last refreshed: 21 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02788292.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing